MeSH tree: C23.550.835.900.356
The Malaghan Institute of Medical Research, in collaboration with Wellington Zhaotai Therapies Limited, today announced results of its phase 1 dose escalation trial of a new third generation anti-CD19 chimeric antigen receptor ...
Dec 11, 2023
0
0
Survival outcomes using chimeric antigen receptor-T cell therapy (CAR-T cell therapy) continue to be impressive for patients with some blood cancers.
Sep 15, 2023
0
2
In recent years, cancer researchers have hailed the arrival of chimeric antigen receptor T cell (CAR T) therapy, which has delivered promising results, transforming the fight against various forms of cancer. The process involves ...
Sep 13, 2023
0
26
The inflammatory response is indispensable for protective immunity, yet microbial pathogens often trigger an excessive response, a "cytokine storm," harmful to the host. Despite recent advances in our understanding of inflammatory ...
Jul 19, 2023
0
1
A single infusion of chimeric antigen receptor T-cell (CAR-T) therapy induced complete response or remission in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), ...
Jul 14, 2023
0
64
Eating an apple a day may keep the doctor away, but having an apple shape is not nearly as healthy. Now, researchers from Japan have shown that people who carry their weight in their bellies may be at greater risk of poor ...
Jun 20, 2023
0
69
Two novel approaches for the treatment of infections caused by antibiotic-resistant superbugs have shown efficacy and good clinical application potential in studies performed by a team from The Hong Kong Polytechnic University ...
Jun 20, 2023
0
37
Researchers have long known that moderate exercise has a beneficial impact on the body's response to inflammation, but what's been less understood is why. New research coming out of York University done on a mouse model suggests ...
Jun 15, 2023
0
7
A treatment that involves genetically modifying the body's own immune cells has been found to cut the risk of disease progression by 74 percent in people with a rare type of blood cancer, results showed Monday.
Jun 5, 2023
0
8
Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (axi-cel) when compared ...
Jun 5, 2023
0
33
